706792-04-3 Usage
General Description
"Benzoic acid, 3-amino-5-ethoxy-, methyl ester (9CI)" is a specialized chemical compound typically found within a scientific or industrial context. It is a derivative of benzoic acid, a weak acid that typically appears as a colorless solid and is a simple carboxylic acid. The additional “3-amino-5-ethoxy” indicates modifications to the benzoic acid molecule, specifically, an additional amino group and an ethoxy group. The “methyl ester” indicates a chemical reaction has taken place, converting the carboxylic acid into an ester, a compound formed from an alcohol and an acid. Typically, such a chemical would be used in laboratories and industries and not commonly found in general day-to-day use. Its exact usage would greatly depend on the context and the desired reaction or substance to be produced.
Check Digit Verification of cas no
The CAS Registry Mumber 706792-04-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,0,6,7,9 and 2 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 706792-04:
(8*7)+(7*0)+(6*6)+(5*7)+(4*9)+(3*2)+(2*0)+(1*4)=173
173 % 10 = 3
So 706792-04-3 is a valid CAS Registry Number.
706792-04-3Relevant articles and documents
CRYSTALLINE FORMS OF TRICYCLIC COMPOUND ACID SALT OR HYDRATE THEREOF, AND METHOD FOR MAKING THEREOF
-
, (2014/12/09)
The present invention relates to a novel crystalline acid salt of a tricyclic derivative or a hydrate thereof and a production method thereof. The crystalline acid salt or the hydrate thereof according to the present invention is stable with respect to hu
ASPARTYL PROTEASE INHIBITORS
-
Page 204-208, (2010/02/05)
The present invention provides compounds having formula (I): wherein R’, R0, R1, X1, R2, R3, R3’, X2, X3, and R4 are as defined herein, and pharmaceuticals compositions thereof. The present invention also provides methods of inhibiting proteases, more specially aspartyl proteases. In certain embodiments, compounds inhibit BACE (β-site APP-cleaving enzyme), and thus are useful in the treatment or prevention of a disease characterized by β-amyloid deposits in the brain (including, but not limited to, Alzheimer’s Disease). The present invention also provides methods for preparing compounds of the invention.